NCT00256100View on ClinicalTrials.gov

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

NATerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Renal Failure
Interventions
DRUG

Fondaparinux Sodium

The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation

Trial Locations (1)

3050

The Royal Melbourne Hospital Intensive Care Unit Grattan Street, Parkville

Sponsors

Lead Sponsor

Melbourne Health
All Listed Sponsors
lead

Melbourne Health

OTHER